欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (6): 623-627.

• 研究原著 • 上一篇    下一篇

复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度

印晓星, 张银娣, 丁黎1, 沈建平, 李丽敏, 邱俊   

  1. 南京医科大学临床药理研究所, 南京210029, 江苏;
    1中国药科大学药物分析教研室, 南京210009, 江苏
  • 收稿日期:2004-01-02 修回日期:2004-03-19 发布日期:2020-11-22

Pharmacokinetics and relative bioavailability of compound metformin hydrochloride and glibenclamide capsule in healthy Chinese volunteers

YIN Xiao-Xing, ZHANG Yi-Di, DING Li1, SHEN Jian-Ping, LI Li-Min, QIU Jun   

  1. Institute of Clinical Pharmacology, Nanjing Medical University, Nanjing 210029, Jiangsu, China;
    1Department of Drug Analysis, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
  • Received:2004-01-02 Revised:2004-03-19 Published:2020-11-22
  • Contact: ZHANG Yin-Di, corresponding author, female, professor, tutor of doctor,specialized in clinical pharmacology.Tel:025-86863159 Fax:025-86863159 E-mail:ydzhang @njmu.edu.cn
  • About author:YIN Xiao-Xing, male, associate professor, PhD candidate.E-mail:yinxx@vip.sina.com

摘要: 目的 研究复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度。 方法 20 名男性志愿者随机交叉口服复方二甲双胍胶囊(试验药) 或合用二甲双胍片 格列本脲片(参比药), HPLC-紫外法和LC-MS 法测定人血浆中二甲双胍和格列本脲浓度, 计算药动学参数和相对生物利用度。 结果 口服试验药和参比药后二甲双胍的Cmax 分别为1.87 ±0.36 和1.77 ±0.35 mg·L-1;Tmax 为1.7 ±0.6和1.8 ±0.5 h;AUC0-∞ 为8.13 ±1.32 和8.62 ±1.47 mg·L-1·h-1 , 格列本脲的Cmax 分别为129.2 ±51.4 和123.9 ±50.7 μg·L-1;Tmax 为2.3 ±0.7 和2.6 ±0.9 h;AUC0-∞为0.690 ±0.228 和0.632 ±0.211 mg·L-1 ·h-1, 以上参数在试验药和参比药之间皆无显著性差异。试验片中二甲双胍和格列本脲相对于参比药的生物利用度分别为95.0 % ±11.5 % 和109.6 %±8.8 %。 结论 复方二甲双胍胶囊中二甲双胍和格列本脲与参比药相比皆生物等效。

关键词: 二甲双胍, 格列本脲, 药物动力学, 生物利用度

Abstract: AIM: To compare pharmacokinetics and relative bioavailability of metformin and glibenclamide in compound metformin hydrochloride and glibenclamide capsule (CMGC) with the reference preparations metformin tablet (MT) and glibenclamide tabet (GT). METHODS: Twenty male healthy volunteers were enrolled in a randomized two-way crossover design with a single-oral dose study.The plasma metformin and glibenclamide concentrations were determined by high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrography (LC-MS), respectively.Pharmacokinetics parameters were calculated and bioequivalability was analyzed by two one-side t-test. RESULTS: The pharmacokinetics parameters of metformin in CMGC and co-administration of metformin glinbenclamide were as following, respectively:Cmax (1.87 ± 0.36 and 1.77 ±0.35) mg·L -1;Tmax (1.7 ±0.6 and 1.8 ±0.5) h;AUC0-∞ (8.13 ±1.32 and 8.62 ±1.47) mg·L -1·h -1, while those of glinbenclamide were as following, respectively: Cmax (129.2 ±51.4 and 123.9 ±50.7) μg·L -1;Tmax(2.3 ±0.7 and 2.6 ±0.9) h;AUC0-∞ (0.690 ±0.228 and 0.632 ±0.211) mg·L -1·h -1.Relative bioavailability of metformin and glibenclamide in CGMC were 95.0 % ±11.5 % and 109.6 %±8.8 %, respectively. CONCLUSION: The main components of CMGC, metformin and glibenclamide, are bioequivalent to the reference tablets, MT and GT.

Key words: metformin, glibenclamide, pharmacokinetics, bioavailability CLC

中图分类号: